XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC). A total of 50 patients with MCRC aged ⩾70 years received oxaliplatin 130 mg m(−2) on day...

Descripción completa

Detalles Bibliográficos
Autores principales: Feliu, J, Salud, A, Escudero, P, Lopez-Gómez, L, Bolaños, M, Galán, A, Vicent, J-M, Yubero, A, Losa, F, De Castro, J, de Mon, M Á, Casado, E, González-Barón, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361238/
https://www.ncbi.nlm.nih.gov/pubmed/16552438
http://dx.doi.org/10.1038/sj.bjc.6603047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361238/
https://www.ncbi.nlm.nih.gov/pubmed/16552438
http://dx.doi.org/10.1038/sj.bjc.6603047

Ejemplares similares